Skip to main content
. Author manuscript; available in PMC: 2017 Jan 16.
Published in final edited form as: J Mol Biol. 2007 May 10;371(1):269–282. doi: 10.1016/j.jmb.2007.05.012

Figure 5.

Figure 5

CD39 is incorporated into HIV-1 clinical isolates expanded in PBMCs and human lymphoid tissue. (a) PBMCs and (b) tonsil tissues were inoculated with HIV-1 clinical isolates 92HT599 (X4-tropic) or 92US657 (R5-tropic). Virus preparations were concentrated and purified from cell-free culture supernatants harvested at seven days, ten days and 13 days post infection. A similar amount of each virus stock, standardized in terms of p24 (i.e. 2 ng of p24), was subjected to the virus capture test using streptavidin-coated beads tagged with biotinylated anti-CD39 or isotype-matched irrelevant (IgG1) antibodies. The amounts of precipitated viruses were estimated with an ELISA specific for the major core viral p24 protein. The data shown are the mean±standard deviation of triplicate samples.